Munich-based smartbax, a biotech startup founded in 2021, has successfully closed a $7.3M Seed funding round to advance its work on innovative antibiotics. The German company is dedicated to combating the rising threat of multidrug-resistant bacteria, a critical global health challenge that demands urgent action.
Smartbax combines cutting-edge technology with deep scientific expertise to design drugs specifically to outsmart bacterial resistance. This capital infusion will fuel its mission to create smarter antibiotics for a healthier tomorrow, addressing one of the most urgent threats to global health.















